Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer.
Marcos Aurélio Fonseca Magalhães FilhoPedro Nazareth AguiarMilena Brachmans Mascarenhas NevesGilberto de Lima LopesAuro Del GiglioPublished in: Einstein (Sao Paulo, Brazil) (2022)
Ado-trastuzumab emtansine is cost-effective from both Brazilian and American perspectives.